trial

Cognition, Functioning and Quality of Life

NCTId NCT00182442
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 80
Sponsored by Hamilton Health Sciences Corporation
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
80
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2003-10
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Hamilton Health Sciences CorporationLead Sponsor
AstraZenecaCollaborator

Investigators

1
Lakshmi P Voruganti, MDPrincipal Investigator

Sites

1 total
Hamilton, Canada

Facts & assertions

3 sourced
Enrollment
80
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Hamilton Health Sciences Corporation
company
collaborator
AstraZeneca
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition Disorders
indication
investigator
Lakshmi P Voruganti, MD
person